77 related articles for article (PubMed ID: 9066616)
21. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
[TBL] [Abstract][Full Text] [Related]
23. Serum MAGE-4 protein in ovarian cancer patients.
Kawagoe H; Yamada A; Matsumoto H; Ito M; Ushijima K; Nishida T; Yakushiji M; Itoh K
Gynecol Oncol; 2000 Mar; 76(3):336-9. PubMed ID: 10684707
[TBL] [Abstract][Full Text] [Related]
24. [C-erbB-2 protein in ovarian epithelial cancer: correlation between expression in tumor tissue and blood levels].
Felip E; Encabo G; Vidal MT; Vera R; del Campo JM; Rubio D
Med Clin (Barc); 1995 Jun; 105(1):5-8. PubMed ID: 7637419
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Abendstein B; Daxenbichler G; Windbichler G; Zeimet AG; Geurts A; Sweep F; Marth C
Anticancer Res; 2000; 20(1B):569-72. PubMed ID: 10769727
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
27. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
28. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
29. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
30. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
31. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
[TBL] [Abstract][Full Text] [Related]
33. C-erbB-2 oncoprotein content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance.
Vizoso F; Villar C; Rodríguez JC; Raigoso P; García-Muñiz JL; Allende MT; García-Moran M
Int J Surg Investig; 2000; 1(6):483-93. PubMed ID: 11729856
[TBL] [Abstract][Full Text] [Related]
34. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
35. [Serum her-2/neu level and related factors in patients with breast cancer].
Yuan P; Xu BH; Zhang C; Qi J
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer.
Tsigris C; Karayiannakis AJ; Syrigos KN; Zbar A; Diamantis T; Kalahanis N; Alexiou D
Anticancer Res; 2002; 22(5):3061-5. PubMed ID: 12530043
[TBL] [Abstract][Full Text] [Related]
37. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
[TBL] [Abstract][Full Text] [Related]
39. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
40. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]